Fyn and Src are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients

Cancer Research

Volumn 69, Issue 17, 2009, Pages 6889-6898

  Lu, Kan V ^a,c   Zhu, Shaojun ^a   Cvrljevic, Anna ^d   Huang, Tiffany T ^a   Sarkaria, Shawn ^a   Ahkavan, David ^a   Dang, Julie ^a   Dinca, Eduard B ^e   Plaisier, Seema B ^a   Oderberg, Isaac ^a   Lee, Yohan ^a   Chen, Zugen ^a   Caldwell, Jeremy S ^f   Xie, Yongmin ^b   Loo, Joseph A ^b   Seligson, David ^a   Chakravari, Arnab ^g   Lee, Francis Y ^h   Weinmann, Roberto ^h   Cloughesy, Timothy F ^a   Nelson, Stanley F ^a   Bergers, Gabriele ^c   Graeber, Thomas ^a   Furnari, Frank B ⁱ   David James, C ^c   Cavenee, Webster K ⁱ   Johns, Terrance G ^j   Mischel, Paul S ^a,k   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d AUSTIN HOSPITAL   (Australia)

^e MAYO CLINIC   (United States)

^f GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^k NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY 806; PROTEIN KINASE FYN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL MOTILITY; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; DRUG SYNERGISM; ENZYME ACTIVATION; GENE SILENCING; GLIOBLASTOMA; HUMANS; MICE; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-FYN; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; THIAZOLES;

EID: 70149112112     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0347     Document Type: Article

References (44)

1. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068
2. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-1812
3. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181 (Pubitemid 46316032)
4. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-1174
5. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006;12:5268-5272 (Pubitemid 44497237)
6. Lal A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 2002;62:3335-3339 (Pubitemid 34651373)
7. Penar PL, Khoshyomn S, Bhushan A, Tritton TR. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery 1997;40:141-151 (Pubitemid 26425661)
8. Martens T, Laabs Y, Gunther HS, et al. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clin Cancer Res 2008;14:5447-5458
9. Martin GS. Rous sarcoma virus: a function required for the maintenance of the transformed state. Nature 1970;227:1021-1023
10. Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 2006;12:1398-1401
11. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4:470-480
12. Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell 2004;6:209-214 (Pubitemid 39222033)
13. Ishizawar RC, Miyake T, Parsons SJ. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene 2007;26:3503-3510 (Pubitemid 46816756)
14. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006;66:5542-5548 (Pubitemid 43927102)
15. Zhang Q, Thomas SM, Xi S, et al. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004;64:6166-6173 (Pubitemid 39129418)
16. Du J, Bernasconi P, Clauser KR, et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 2009;27:77-83.
17. Freije WA, Castro-Vargas FE, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004;64:6503-6510 (Pubitemid 39297907)
18. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 2001;98:31-36 (Pubitemid 32095858)
19. Skaggs BJ, Gorre ME, Ryvkin A, et al. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A 2006;103:19466-19471 (Pubitemid 46026054)
20. Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene 2004;23:1283-1290 (Pubitemid 38297183)
21. Wang MY, Lu KV, Zhu S, et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 2006;66:7864-7869 (Pubitemid 44299148)
22. Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest 2004;84:8-20.
23. Blouw B, Song H, Tihan T, et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003;4:133-146 (Pubitemid 37040829)
24. Du R, Lu KV, Petritsch C, et al. HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13:206-220 (Pubitemid 351318372)
25. Sarkaria JN, Yang L, Grogan PT, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 2007;6:1167-1174 (Pubitemid 46554588)
26. Johns TG, Perera RM, Vernes SC, et al. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res 2007;13:1911-1925
27. Johns TG, Stockert E, Ritter G, et al. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer 2002;98:398-408. (Pubitemid 34188683)
28. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-2024 (Pubitemid 41609094)
29. Choe G, Horvath S, Cloughesy TF, et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003;63:2742-2746 (Pubitemid 36667143)
30. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-173 (Pubitemid 43357943)
31. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401. (Pubitemid 38938156)
32. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome- positive leukemias. N Engl J Med 2006;354:2531-2541 (Pubitemid 43882349)
33. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the Src and Abl kinases, selectively inhibits growth of basal-type/"triplenegative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007;105:319-326
34. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9189 (Pubitemid 41507982)
35. Serrels A, Macpherson IR, Evans TR, et al. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 2006;5:3014-3022 (Pubitemid 46092042)
36. Luo FR, Yang Z, Camuso A, et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 2006;12:7180-7186 (Pubitemid 44974520)
37. Dinca EB, Sarkaria JN, Schroeder MA, et al. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg 2007;107:610-616
38. Pandita A, Aldape KD, Zadeh G, Guha A, James CD. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 2004;39:29-36. (Pubitemid 37475250)
39. Koppikar P, Choi SH, Egloff AM, et al. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res 2008;14:4284-4291
40. Weissenberger J, Steinbach JP, Malin G, Spada S, Rulicke T, Aguzzi A. Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene 1997;14:2005-2013 (Pubitemid 27237002)
41. Stettner MR, Wang W, Nabors LB, et al. Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res 2005;65:5535-5543 (Pubitemid 40911153)
42. Kleber S, Sancho-Martinez I, Wiestler B, et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008;13:235-248 (Pubitemid 351324880)
43. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500 (Pubitemid 38720929)
44. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12:7232-7241 (Pubitemid 46095394)